Brief: Vaccinex Announces Activation Of Clinical Sites To Enroll Patients In Studies Of Pepinemab As Single Agent In Alzheimer’S Disease
08/06/2021 12:15
June 8 (Reuters) - Vaccinex Inc VCNX.O :
* VACCINEX ANNOUNCES ACTIVATION OF CLINICAL SITES TO ENROLL
PATIENTS IN STUDIES OF PEPINEMAB AS SINGLE AGENT IN ALZHEIMER’S
DISEASE AND IN COMBINATION WITH KEYTRUDA® IN ADVANCED, RECURRENT
OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)
* VACCINEX INC - PLANS TO ACTIVATE AT LEAST 13 U.S. SITES
FOR
ALZHEIMER STUDY AND 18 U.S. SITES FOR HNSCC
Source text for Eikon: ID:nGNX8gFzFp
Further company coverage: VCNX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vaccinex
See all newsBrief: Vaccinex Reports Third Quarter 2024 Financial Results And Provides Corporate Update
Brief: Vaccinex Says On Oct 7, Got Letter From The Nasdaq Listing Staff Stating That Co Had Not Regained Compliance With The Equity Standard
Brief: VaccinexExercise Of Warrants For $6.2 Million In Gross Proceeds
Brief: Vaccinex Provides Update On New Findings For Signal-Ad Phase 1B/2 Trial Of Pepinemab In Alzheimer’S Disease
Brief: Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease